The Urgent Need for New Depression Treatments

Despite the availability of numerous drugs against depression, a meaningful portion of individuals, roughly one-third, grappling with severe depression find themselves resistant to conventional treatments. Furthermore,existing medications often require weeks to manifest their effects,leaving patients vulnerable to the debilitating symptoms of this condition. This underscores the critical need for new molecules that are fast, safe and effective in combating depression.

Nitrous Oxide: an Unexpected Antidepressant?

Emerging research is exploring the potential of nitrous oxide, commonly known as laughing gas, as a rapid-acting antidepressant. Preliminary clinical studies have yielded promising results, and a recent examination published in Nature communications offers compelling evidence of its effectiveness. The study sheds light on the brain mechanisms through which nitrous oxide may induce mood improvement following exposure.

From anesthetic to Psychiatric Treatment: A Paradigm Shift

The growing interest in nitrous oxide stems from the success of ketamine, another anesthetic drug now recognized for its therapeutic applications in treating psychiatric disorders such as depression and posttraumatic stress disorder. Inspired by ketamine’s efficacy, researchers have turned their attention to nitrous oxide, a long-standing anesthetic agent, particularly in dentistry, known for its affordability and safety profile.

Rapid Action, Lasting effects: Unraveling the mystery

A clinical trial conducted in 2021 indicated that low doses of nitrous oxide, below those inducing euphoria, could alleviate severe depression symptoms in treatment-resistant patients after a single inhalation session, with effects lasting up to two weeks. However, the underlying mechanisms remained unclear. One of the key advantages of nitrous oxide is its short half-life of approximately five minutes, facilitating rapid excretion from the body. This characteristic makes it ideal for fast anesthesia. Yet, the sustained antidepressant effects observed in studies presented a puzzle: how can a drug that vanishes from the body within minutes produce mood improvements lasting for days or weeks?

A Journey into the Past to Unlock the Future

According to Joseph Cichon, an anesthetist at the University of Pennsylvania involved in the recent research, Nitrogen oxide is the oldest anesthetic than we have, it has been used for more than 180 years, it costs about 20 dollars the bottle and we continue to discover new things about its potential. I felt a bit like Indiana Jones, traveling to the past to solve the mystery of an old drug.

Challenging the NMDA Receptor Theory

The prevailing theory regarding the antidepressant action of analgesics like ketamine and nitrous oxide centered on their ability to block the NMDA receptor, a brain receptor involved in memory and learning. Though, this mechanism seemed incompatible with the fleeting presence of nitrous oxide in the body. Consequently, the researchers embarked on a more in-depth investigation to understand what happens in the brain when exposed to this gas.

Unveiling the Brain’s Response to Nitrous Oxide

Using advanced calcium imaging techniques to monitor neuronal activity in real-time, researchers observed the brains of mice subjected to chronic stress, a validated animal model for studying depression. Exposure to nitrous oxide revealed a potential explanation: the reactivation of a group of neurons located in the internal pyramidal layer of the cingulate cortex, a brain region associated with emotion and mood regulation.

In cases of stress-induced depression, these neurons are typically inactive in both animal and human brains. However, upon exposure to nitrous oxide, the neurons in the mice rapidly regained their excitability and remained in this state even after the drug was eliminated from the body.

A New Avenue for Depression Treatment

Peter Nagele, professor of anesthetic psychiatry at the University of Chicago and coordinator of the research, concludes, these results show that there may be more than one way to achieve our goal in the treatment of depression. NMDA receptors are one of them, but what we observe with nitrogen oxide suggests that there is another way to return the activity to brain circuits. It is an exciting discovery because it expands our understanding of how we can address depression from multiple angles.

The Road Ahead: Clinical Trials and New Drug Growth

While it remains premature to definitively declare laughing gas as a viable long-term treatment option,the discovery of its mechanism of action paves the way for exploring new drugs that mimic its effects.Given the pressing need for novel pharmacological interventions for patients with severe treatment-resistant depression, this research represents a significant step forward.